Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Type:
Application
Filed:
April 29, 2020
Publication date:
July 21, 2022
Applicant:
AiCuris GmbH & Co. KG
Inventors:
Susanne BONSMANN, Alastair DONALD, Andreas URBAN, Jasper SPRINGER, Elena DETTA
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Type:
Application
Filed:
April 29, 2020
Publication date:
July 21, 2022
Applicant:
AiCuris GmbH & Co. KG
Inventors:
Susanne BONSMANN, Alastair DONALD, Andreas URBAN, Thomas GOLDNER, Miquel Angel PERICAS BRONDO, Esther Alza BARRIOS, Elena DETTA, Justine RAYMOND
Abstract: The present invention relates to the field of anti-viral active agents, particularly to salts, more particularly to a maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, to pharmaceutical formulations thereof as well as to methods for the production of these salts. The present invention also relates to the use of theses salts and of respective pharmaceutical formulations thereof in methods of treatment and/or prevention of human herpes simplex virus infections, particularly infections caused by HSV-1 and HSV-2.
Type:
Application
Filed:
January 26, 2022
Publication date:
May 19, 2022
Applicant:
AICURIS GMBH & CO. KG
Inventors:
Yogeshwar BACHHAV, Wilfried SCHWAB, Alexander BIRKMANN, Susanne BONSMANN, Thomas GOLDNER
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Abstract: The present invention relates to the field of anti-viral active agents, particularly to salts, more particularly to a maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, to pharmaceutical formulations thereof as well as to methods for the production of these salts. The present invention also relates to the use of theses salts and of respective pharmaceutical formulations thereof in methods of treatment and/or prevention of human herpes simplex virus infections, particularly infections caused by HSV-1 and HSV-2.
Type:
Grant
Filed:
November 28, 2017
Date of Patent:
March 8, 2022
Assignee:
AICURIS GMBH & CO. KG
Inventors:
Yogeshwar Bachhav, Wilfried Schwab, Alexander Birkmann, Susanne Bonsmann, Thomas Goldner
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Type:
Application
Filed:
November 1, 2019
Publication date:
January 13, 2022
Applicant:
AICURIS GMBH & CO. KG
Inventors:
Alastair DONALD, Andreas URBAN, Susanne BONSMANN
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Type:
Application
Filed:
November 1, 2019
Publication date:
January 13, 2022
Applicant:
AiCuris GmbH & Co. KG
Inventors:
Alastair DONALD, Andreas URBAN, Susanne BONSMANN
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Type:
Application
Filed:
November 1, 2019
Publication date:
January 13, 2022
Applicant:
AICURIS GMBH & CO. KG
Inventors:
Alastair DONALD, Andreas URBAN, Susanne BONSMANN
Abstract: The present invention relates to field of intravaginally applicable devices that release antiviral compounds. In particular, the present invention relates to vaginal rings comprising a matrix releasing at least one antivirally active compound, in particular anti-herpetic compound N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide (in the following also referred to as “Pritelivir”) or salts thereof. The present invention therefore relates to the treatment and prevention of herpes infections.
Type:
Grant
Filed:
June 28, 2018
Date of Patent:
January 4, 2022
Assignee:
AICURIS GMBH & CO. KG
Inventors:
Yogeshwar Bachhav, Susanne Bonsmann, Tamara Pfaff, Alexander Birkmann, Karl Malcolm
Abstract: The present invention generally provides for a novel NEC-targeted strategy for the development of antiherpesviral drugs as well as for a novel antiviral strategy targeting the viral-cellular nuclear egress complex (NEC) for a small molecule-based therapy or prophylaxis to control infections with human cytomegalovirus or other pathogenic viruses of the group of the Herpesviridae. Methods for screening agents/compounds/small molecules modulating/inhibiting the nuclear egress complex of Herpesviridae are provided as well. Specifically novel drug targets of the viral nuclear egress complex of viruses of the Herpesviridae are provided.
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Type:
Application
Filed:
November 1, 2019
Publication date:
November 18, 2021
Applicant:
AICURIS GMBH & CO. KG
Inventors:
Alastair DONALD, Andreas URBAN, Susanne BONSMANN
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Abstract: The present invention relates to new combination therapies of HBV-infected individuals using a Parapoxvirus ovis (PPVO) and at least one further antiviral drug, e.g., nucleoside inhibitors, such as Entecavir. The methods and combination products according to the present invention are safe and suitable for the induction of a functional cure in chronically HBV-infected patients.
Type:
Application
Filed:
September 7, 2018
Publication date:
August 20, 2020
Applicant:
AiCuris GmbH & Co. KG
Inventors:
Daniela PAULSEN, Andreas URBAN, Ibironke ADDY, Tamara PFAFF, Stephan MENNE, Willem SLOOT
Abstract: The invention relates to pharmaceutical compositions, particularly for intravenous administration, containing {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in combination with at least one of the cyclodextrin excipients, lysine and arginine; the method for its production; and its use in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses.
Type:
Grant
Filed:
February 28, 2013
Date of Patent:
March 31, 2020
Assignee:
AICURIS GMBH & CO. KG
Inventors:
Kerstin Paulus, Wilfried Schwab, Dominique Grunder, Peter Van Hoogevest